Gabather is a pharmaceutical company whose business focus is to develop drug candidates for the treatment of neurological diseases. The focus is particularly on the stimulation of gamma-aminobutyric acid, which is the main inhibitory neurotransmitter in the brain. The drug candidates are patented on a global level. Gabather was established in 2014 and is headquartered in Malmö.
* Phase II clinical trial activated * Cost control is still kept strict * We keep our fair value of SEK 0.06 per share Gabather's first report of 2026 came in close to our estimates, with an EBIT of KSEK -1 052 against our projected KSEK -1 136. The ...
* Approval to initiate the financed TOTEMS study * Patient enrolment imminent Gabather has announced the initiation of the TOTEMS study, a phase II clinical trial evaluating the drug candidate GT-002 in patients with schizophrenia spectrum disorders....
* Exercise of warrants and a directed share issue extends runway * Phase II clinical trial expected to start very soon * After dilution, our fair value amounts to SEK 0.06 per share Gabather’s Q4 report showed lower-than-expected costs, primarily due...
* A TOTEMS study article published in Frontiers in Psychiatry * The exercise of TO 7 warrants provides some financial relief * We keep our fair value of SEK 0.092 per share Gabather's reported figures in its recent Q3 report were close to our estimates...
* Issues with clinical test material delays TOTEMS-study * New chairman elected at the AGM * We keep our fair value of SEK 0.092 per share Before releasing its Q2 2025 report, Gabather announced that the TOTEMS-study would be delayed due to issues with...
• Novel therapeutics addressing the GABAA receptor system in the CNS • An exploratory phase II study in schizophrenia is ongoing • We initiate coverage with a fair value of SEK 0.092 per share Gabather is a drug developer in precision medicine targeting...
Gabather AB (“Gabather” or “the Company”) is advancing GT-002, a first-in-class GABAA-modulator, through Phase II clinical trials, targeting cognitive dysfunction. With a fully funded schizophrenia Phase II trial and a planned expansion into Phase II...